<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p90" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_90{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_90{left:341px;bottom:30px;}
#t3_90{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_90{left:377px;bottom:30px;}
#t5_90{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_90{left:540px;bottom:30px;}
#t7_90{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_90{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_90{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_90{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_90{left:285px;bottom:827px;letter-spacing:-0.29px;}
#tc_90{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_90{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_90{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_90{left:1127px;bottom:28px;letter-spacing:0.26px;}
#tg_90{left:36px;bottom:226px;}
#th_90{left:46px;bottom:220px;letter-spacing:0.12px;}
#ti_90{left:78px;bottom:220px;letter-spacing:0.08px;word-spacing:-0.02px;}
#tj_90{left:377px;bottom:220px;letter-spacing:0.12px;}
#tk_90{left:407px;bottom:220px;letter-spacing:0.13px;}
#tl_90{left:481px;bottom:220px;}
#tm_90{left:36px;bottom:210px;}
#tn_90{left:46px;bottom:204px;letter-spacing:0.12px;}
#to_90{left:45px;bottom:187px;letter-spacing:0.13px;word-spacing:-0.04px;}
#tp_90{left:45px;bottom:170px;letter-spacing:0.09px;word-spacing:-0.13px;}
#tq_90{left:45px;bottom:153px;letter-spacing:0.12px;}
#tr_90{left:45px;bottom:136px;letter-spacing:0.13px;}
#ts_90{left:45px;bottom:120px;letter-spacing:0.13px;}
#tt_90{left:432px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#tu_90{left:759px;bottom:786px;letter-spacing:-0.12px;}
#tv_90{left:36px;bottom:748px;letter-spacing:-0.1px;}
#tw_90{left:36px;bottom:729px;letter-spacing:-0.1px;word-spacing:-0.13px;}
#tx_90{left:36px;bottom:711px;letter-spacing:-0.32px;word-spacing:0.23px;}
#ty_90{left:41px;bottom:693px;}
#tz_90{left:58px;bottom:693px;letter-spacing:-0.09px;}
#t10_90{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t11_90{left:63px;bottom:656px;}
#t12_90{left:76px;bottom:656px;letter-spacing:-0.09px;}
#t13_90{left:41px;bottom:638px;}
#t14_90{left:58px;bottom:638px;letter-spacing:-0.09px;}
#t15_90{left:63px;bottom:619px;}
#t16_90{left:76px;bottom:619px;letter-spacing:-0.09px;}
#t17_90{left:36px;bottom:601px;letter-spacing:-0.1px;}
#t18_90{left:36px;bottom:583px;letter-spacing:-0.1px;}
#t19_90{left:423px;bottom:590px;}
#t1a_90{left:36px;bottom:545px;letter-spacing:0.33px;}
#t1b_90{left:36px;bottom:527px;letter-spacing:-1.01px;}
#t1c_90{left:36px;bottom:508px;letter-spacing:-0.09px;}
#t1d_90{left:36px;bottom:490px;letter-spacing:-0.1px;}
#t1e_90{left:41px;bottom:472px;}
#t1f_90{left:58px;bottom:472px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1g_90{left:58px;bottom:453px;letter-spacing:-0.1px;}
#t1h_90{left:120px;bottom:461px;}
#t1i_90{left:63px;bottom:435px;}
#t1j_90{left:76px;bottom:435px;letter-spacing:-0.09px;}
#t1k_90{left:41px;bottom:417px;}
#t1l_90{left:58px;bottom:417px;letter-spacing:-0.09px;}
#t1m_90{left:63px;bottom:398px;}
#t1n_90{left:76px;bottom:398px;letter-spacing:-0.09px;}
#t1o_90{left:36px;bottom:380px;letter-spacing:-0.1px;}
#t1p_90{left:423px;bottom:388px;}
#t1q_90{left:36px;bottom:348px;letter-spacing:-0.1px;}
#t1r_90{left:36px;bottom:330px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1s_90{left:528px;bottom:235px;}
#t1t_90{left:538px;bottom:229px;letter-spacing:0.13px;}
#t1u_90{left:537px;bottom:212px;letter-spacing:0.12px;word-spacing:-0.15px;}
#t1v_90{left:537px;bottom:195px;letter-spacing:0.12px;}
#t1w_90{left:537px;bottom:179px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1x_90{left:537px;bottom:162px;letter-spacing:0.12px;word-spacing:-0.14px;}
#t1y_90{left:537px;bottom:145px;letter-spacing:0.14px;}
#t1z_90{left:537px;bottom:128px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t20_90{left:537px;bottom:111px;letter-spacing:0.08px;word-spacing:0.05px;}
#t21_90{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_90{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_90{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_90{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_90{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_90{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_90{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_90{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_90{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_90{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_90{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_90{font-size:17px;font-family:Webdings_k6;color:#000;}
.sb_90{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_90{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sd_90{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts90" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg90Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg90" style="-webkit-user-select: none;"><object width="1210" height="935" data="90/90.svg" type="image/svg+xml" id="pdf90" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_90" class="t s0_90">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_90" class="t s1_90">® </span>
<span id="t3_90" class="t s0_90">(NCCN </span>
<span id="t4_90" class="t s1_90">® </span>
<span id="t5_90" class="t s0_90">), All rights reserved. NCCN Guidelines </span>
<span id="t6_90" class="t s1_90">® </span>
<span id="t7_90" class="t s0_90">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_90" class="t s2_90">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_90" class="t s2_90">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_90" class="t s3_90">NCCN Guidelines Version 4.2024 </span>
<span id="tb_90" class="t s3_90">Mucosal Melanoma </span>
<span id="tc_90" class="t s4_90">NCCN Guidelines Index </span>
<span id="td_90" class="t s4_90">Table of Contents </span>
<span id="te_90" class="t s4_90">Discussion </span>
<span id="tf_90" class="t s5_90">MM-A </span>
<span id="tg_90" class="t s6_90">1 </span>
<span id="th_90" class="t s7_90">See </span><span id="ti_90" class="t s8_90">Principles of Radiation Techniques (RAD-A) </span><span id="tj_90" class="t s7_90">and </span><span id="tk_90" class="t s8_90">Discussion</span><span id="tl_90" class="t s7_90">. </span>
<span id="tm_90" class="t s6_90">2 </span>
<span id="tn_90" class="t s7_90">Recent studies suggest that increased toxicity may occur when RT </span>
<span id="to_90" class="t s7_90">is used in combination with BRAF inhibitors [Anker CJ, Grossmann </span>
<span id="tp_90" class="t s7_90">KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF </span>
<span id="tq_90" class="t s7_90">inhibitor and radiation treatment: Consensus guidelines from the </span>
<span id="tr_90" class="t s7_90">Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol </span>
<span id="ts_90" class="t s7_90">Biol Phys 2016;95:632-646]. </span>
<span id="tt_90" class="t s5_90">PRINCIPLES OF RADIATION THERAPY </span>
<span id="tu_90" class="t s9_90">1,2 </span>
<span id="tv_90" class="t s5_90">DEFINITIVE: </span>
<span id="tw_90" class="t s5_90">RT Alone (unresectable locally advanced melanoma): </span>
<span id="tx_90" class="t s5_90">• PTV: </span>
<span id="ty_90" class="t sa_90"></span><span id="tz_90" class="t sb_90" data-mappings='[[94,"fi"]]'>High risk: Primary tumor and involved lymph nodes [this includes possible local subclinical inﬁltration at the primary site and at the high- </span>
<span id="t10_90" class="t s5_90">risk-level lymph node(s)] </span>
<span id="t11_90" class="t sc_90">◊ </span><span id="t12_90" class="t s5_90">66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction) daily Monday–Friday in 6–7 weeks </span>
<span id="t13_90" class="t sa_90"></span><span id="t14_90" class="t s5_90">Low to intermediate risk: Sites suspected of subclinical spread </span>
<span id="t15_90" class="t sc_90">◊ </span><span id="t16_90" class="t s5_90">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t17_90" class="t s5_90">• Palliative RT doses and schedules may be considered. </span>
<span id="t18_90" class="t s5_90">• Optional dosing schedules may be considered. </span>
<span id="t19_90" class="t s9_90">3 </span>
<span id="t1a_90" class="t s5_90">POSTOPERATIVE: </span>
<span id="t1b_90" class="t s5_90">RT: </span>
<span id="t1c_90" class="t s5_90">• Preferred interval between resection and postoperative RT is &lt;6 weeks. </span>
<span id="t1d_90" class="t s5_90">• PTV </span>
<span id="t1e_90" class="t sa_90"></span><span id="t1f_90" class="t s5_90">High risk: Adverse pathologic features &gt;2 nodes, single node &gt;3 cm, extranodal extension, recurrence in nodal basin after previous </span>
<span id="t1g_90" class="t s5_90">surgery </span>
<span id="t1h_90" class="t s9_90">2 </span>
<span id="t1i_90" class="t sc_90">◊ </span><span id="t1j_90" class="t s5_90">60–66 Gy (2.0 Gy/fraction; daily Monday–Friday) in 6–6.5 weeks </span>
<span id="t1k_90" class="t sa_90"></span><span id="t1l_90" class="t s5_90">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1m_90" class="t sc_90">◊ </span><span id="t1n_90" class="t s5_90">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1o_90" class="t s5_90">• Optional dosing schedules may be considered. </span>
<span id="t1p_90" class="t s9_90">3 </span>
<span id="t1q_90" class="t s5_90">Either IMRT (preferred) or 3D-CRT is recommended. Proton therapy can be considered when normal tissue constraints cannot be met by </span>
<span id="t1r_90" class="t s5_90">photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t1s_90" class="t s6_90">3 </span>
<span id="t1t_90" class="t s7_90">Optional dose schedules include 48–50 Gy (2.4–3.0 Gy/fraction) and 30–36 Gy (6 Gy/fraction) </span>
<span id="t1u_90" class="t s7_90">(Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation </span>
<span id="t1v_90" class="t s7_90">alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy </span>
<span id="t1w_90" class="t s7_90">for melanoma: a randomised trial. Lancet Oncol 2012;13:589-597; Ballo MT, Bonnen MD, </span>
<span id="t1x_90" class="t s7_90">Garden AS, et al. Adjuvant irradiation for cervical node metastases from melanoma. Cancer </span>
<span id="t1y_90" class="t s7_90">2003;97:1789-1796; and Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma </span>
<span id="t1z_90" class="t s7_90">of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson </span>
<span id="t20_90" class="t s7_90">Cancer Center. Cancer 2010;116:2215-2223). </span>
<span id="t21_90" class="t sd_90">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
